|
1
|
National Comprehensive Cancer Network, .
Clinical practice guidelines in oncology head and neck cancers,
version 2. National Comprehensive Cancer Network. 2021.
|
|
2
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Akali NR, Buggaveeti R, Sukumaran SV,
Balasubramanian D, Iyer S and Thankappan K: Prior chemoradiotherapy
and pathological perineural invasion predict the survival outcomes
of salvage surgery in head and neck squamous cell carcinoma. Head
Neck. 43:874–883. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh
C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ and Yen TC: Salvage
therapy in relapsed squamous cell carcinoma of the oral cavity: How
and when? Cancer. 112:94–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nandy K, Rai S, Bhatt S, Puj K, Rathod P
and Gangopadhyay A: Salvage surgery for recurrent carcinoma of the
oral cavity: Assessment of prognostic factors. Int J Oral
Maxillofac Surg. 51:602–611. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsuchihashi H, Naruse T, Yanamoto S,
Okuyama K, Furukawa K, Omori K and Umeda M: Selective inhibition of
PI3K110α as a novel therapeutic strategy for cetuximab-resistant
oral squamous cell carcinoma. Oncol Rep. 44:863–872. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Horn D, Zittel S, Moratin J, Metzger K,
Ristow O, Krisam J, Bodem J, Engel M, Freudlsperger C, Hoffmann J
and Freier K: Prospective feasibility analysis of salvage surgery
in recurrent oral cancer in terms of quality of life. Oral Oncol.
102:1045802020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hecht M, Hahn D, Wolber P, Hautmann MG,
Reichert D, Weniger S, Belka C, Bergmann T, Göhler T, Welslau M, et
al: A prospective real-world multi-center study to evaluate
progression-free and overall survival of radiotherapy with
cetuximab and platinum-based chemotherapy with cetuximab in locally
recurrent head and neck cancer. Cancers (Basel). 13:34132021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Balermpas P, Keller C, Hambek M,
Wagenblast J, Seitz O, Rödel C and Weiss C: Reirradiation with
cetuximab in locoregional recurrent and inoperable squamous cell
carcinoma of the head and neck: Feasibility and first efficacy
results. Int J Radiat Oncol Biol Phys. 83:e377–e383. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lartigau EF, Tresch E, Thariat J, Graff P,
Coche-Dequeant B, Benezery K, Schiappacasse L, Degardin M, Bondiau
PY, Peiffert D, et al: Multi institutional phase II study of
concomitant stereotactic reirradiation and cetuximab for recurrent
head and neck cancer. Radiother Oncol. 109:281–285. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Naruse T, Yanamoto S, Otsuru M, Yamakawa
N, Kirita T, Shintani Y, Matsumura T, Okura M, Sasaki M, Ota Y, et
al: Multicenter retrospective study of weekly cetuximab plus
paclitaxel for recurrent or metastatic oral squamous cell
carcinoma. Anticancer Res. 41:5785–5791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yanamoto S, Umeda M, Kioi M, Kirita T,
Yamashita T, Hiratsuka H, Yokoo S, Tanzawa H, Uzawa N, Shibahara T,
et al: Multicenter retrospective study of cetuximab plus
platinum-based chemotherapy for recurrent or metastatic oral
squamous cell carcinoma. Cancer Chemother Pharmacol. 81:549–554.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kojima Y, Yanamoto S, Umeda M, Kawashita
Y, Saito I, Hasegawa T, Komori T, Ueda N, Kirita T, Yamada SI, et
al: Relationship between dental status and development of
osteoradionecrosis of the jaw: A multicenter retrospective study.
Oral Surg Oral Med Oral Pathol Oral Radiol. 124:139–145. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saito I, Hasegawa T, Kawashita Y, Kato S,
Yamada SI, Kojima Y, Ueda N, Umeda M, Shibuya Y, Kurita H, et al:
Association between dental extraction after radiotherapy and
osteoradionecrosis: A multi-centre retrospective study. Oral Dis.
28:1181–1187. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Argiris A, Lee SC, Feinstein T, Thomas S,
Branstetter BF IV, Seethala R, Wang L, Gooding W, Grandis JR and
Ferris RL: Serum biomarkers as potential predictors of antitumor
activity of cetuximab-containing therapy for locally advanced head
and neck cancer. Oral Oncol. 47:961–966. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oliveras-Ferraros C, Vazquez-Martin A,
Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño
R, Báez L, Martin-Castillo B, et al: Interferon/STAT1 and
neuregulin signaling pathways are exploratory biomarkers of
cetuximab (Erbitux®) efficacy in KRAS wild-type squamous
carcinomas: A pathway-based analysis of whole human-genome
microarray data from cetuximab-adapted tumor cell-line models. Int
J Oncol. 39:1455–1479. 2011.PubMed/NCBI
|
|
18
|
Schmitz S, Bindea G, Albu RI, Mlecnik B
and Machiels JP: Cetuximab promotes epithelial to mesenchymal
transition and cancer associated fibroblasts in patients with head
and neck cancer. Oncotarget. 6:34288–34299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kimura I, Kitahara H, Ooi K, Kato K,
Noguchi N, Yoshizawa K, Nakamura H and Kawashiri S: Loss of
epidermal growth factor receptor expression in oral squamous cell
carcinoma is associated with invasiveness and
epithelial-mesenchymal transition. Oncol Lett. 11:201–207. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Naruse T, Tokuhisa M, Yanamoto S, Sakamoto
Y, Okuyama K, Tsuchihashi H and Umeda M: Lower gingival squamous
cell carcinoma with brain metastasis during long-term cetuximab
treatment: A case report. Oncol Lett. 15:7158–7162. 2018.PubMed/NCBI
|
|
21
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
